Exhibit 99.1 28 April 2023 PureTech Health plc PureTech Announces Annual Results for Year Ended December 31, 2022 Strong capital base with PureTech level cash, cash equivalents and short-term investments of $339.5 million1 and consolidated cash, cash equivalents and short-term investments of$350.1 million,2 as of December 31, 2022. Rapid advancement of PureTech’s Wholly Owned Pipeline, with four clinical stage therapeutic candidates, including LYT-100 (ongoing registration- enabling trial in IPF), LYT-300 ...